There is an increasing trend of aging in our country, and sarcopenia, as a geriatric syndrome associated with various adverse health outcomes, has been extensively studied in recent years. Myasthenia gravis manifests as an age-related decrease in skeletal muscle mass, strength and function. Recent studies have shown that sarcopenia is closely related to chronic heartfailure (CHF), with most CHF patients showing a reduction in peripheral skeletal muscle tissue early in the disease, and even older CHF patients with preserved ejection fraction have significantly reduced non-lipid mass in the legs and whole body, and is closely associated with decreased physical activity. I. Definition of sarcopenia Sarcopenia, also known as sarcopenia, is an age-related geriatric syndrome characterized by progressive loss of muscle mass, strength, and function and is a powerful factor in frailty, disability, and death in the elderly. II. Epidemiology of chronic heart failure combined with sarcopenia Sarcopenia affects 5% to 13% of 60- to 70-year-olds and up to 50% of those in their 80s, and the prevalence of sarcopenia in the general elderly population in Asia is 4.1% to 11.5%. The prevalence of sarcopenia in patients with CHF is as high as 20% compared to controls of the same age. Although myasthenia gravis is an age-related disease, CHF can accelerate the onset of skeletal muscle lesions and reduce peripheral skeletal muscle tissue in the early stages of the disease. As a complication of CHF, myasthenia gravis seriously affects the progress and prognosis of CHF. The diagnosis of myasthenia gravis: 1. reduced muscle mass. 2. reduced muscle strength. 3. reduced muscle function. Meet the 1st, and meet both 2 and (or 3) can be diagnosed. V. Possible mechanisms of chronic heart failure combined with sarcopenia 1. Imbalance of protein metabolism: Heart failure patients have enhanced proteolytic metabolism, and the ubiquitin-proteasome system and autophagy-lysosome system are involved in the breakdown of skeletal muscle proteins. 2. Oxidative stress: Oxidative stress is one of the important signs of several severe pathological states such as heart failure, and also High levels of oxidative stress can cause damage to the mitochondria of myocytes, which in turn leads to impaired myocyte function. The treatment of chronic heart failure combined with sarcopenia: growth hormone, gastric starvation and vitamin D supplements are also hot spots in the current research of hormone therapy, but there is a lack of research on the application in heart failure patients. The results of small clinical trials show that ACEI and ARB can play a role in protecting skeletal muscle by promoting endothelial cell proliferation, increasing skeletal muscle blood flow, improving insulin resistance and mitochondrial function, and reducing the levels of inflammatory factors IL-6 and TNF-α, thus improving exercise tolerance in patients with heart failure. VII. Prognosis of chronic heart failure combined with sarcopenia A retrospective study of 160 cases of HF revealed that the risk of all-cause death at 1 year was 4.5 times higher in 52 patients with sarcopenia than in the rest of the population.